skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Relapse Analysis of Irradiated Patients Within the HD15 Trial of the German Hodgkin Study Group

Abstract

Purpose: To determine, in the setting of advanced-stage of Hodgkin lymphoma (HL), whether relapses occur in the irradiated planning target volume and whether the definition of local radiation therapy (RT) used by the German Hodgkin Study Group (GHSG) is adequate, because there is no harmonization of field and volume definitions among the large cooperative groups in the treatment of advanced-stage HL. Methods and Materials: All patients with residual disease of ≥2.5 cm after multiagent chemotherapy (CTX) were evaluated using additional positron emission tomography (PET), and those with a PET-positive result were irradiated with 30 Gy to the site of residual disease. We re-evaluated all sites of disease before and after CTX, as well as the PET-positive residual tumor that was treated in all relapsed patients. Documentation of radiation therapy (RT), treatment planning procedures, and portal images were carefully analyzed and compared with the centrally recommended RT prescription. The irradiated sites were compared with sites of relapse using follow-up computed tomography scans. Results: A total of 2126 patients were enrolled, and 225 patients (11%) received RT. Radiation therapy documents of 152 irradiated patients (68%) were analyzed, with 28 irradiated patients (11%) relapsing subsequently. Eleven patients (39%) had an in-field relapse, 7 patients (25%) relapsed outsidemore » the irradiated volume, and an additional 10 patients (36%) showed mixed in- and out-field relapses. Of 123 patients, 20 (16%) with adequately performed RT relapsed, compared with 7 of 29 patients (24%) with inadequate RT. Conclusions: The frequency and pattern of relapses suggest that local RT to PET-positive residual disease is sufficient for patients in advanced-stage HL. Insufficient safety margins of local RT may contribute to in-field relapses.« less

Authors:
;  [1]; ; ;  [2];  [3];  [1];  [4];  [5];  [6];  [7];  [8];  [1];  [9];  [3]
  1. Department of Radiation Oncology, University of Münster, Münster (Germany)
  2. Department of Nuclear Medicine, University of Cologne, Cologne (Germany)
  3. First Department of Internal Medicine, University of Cologne, Cologne (Germany)
  4. Department of Radiation Oncology, University of Marburg, Marburg (Germany)
  5. Department of Radiation Oncology, University Heidelberg, Heidelberg (Germany)
  6. Department of Radiation Oncology, University of Innsbruck, Innsbruck (Austria)
  7. Department of Radiation Oncology, University of Mainz, Mainz (Germany)
  8. Department of Radiation Oncology, Klinikum Bremen-Mitte, Bremen (Germany)
  9. Department of Radiation Oncology, University of Cologne, Cologne (Germany)
Publication Date:
OSTI Identifier:
22458692
Resource Type:
Journal Article
Journal Name:
International Journal of Radiation Oncology, Biology and Physics
Additional Journal Information:
Journal Volume: 92; Journal Issue: 1; Other Information: Copyright (c) 2015 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0360-3016
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; CHEMOTHERAPY; COMPARATIVE EVALUATIONS; COOPERATIVES; DOCUMENTATION; HODGKINS DISEASE; IMAGES; IRRADIATION; PATIENTS; PLANNING; POSITRON COMPUTED TOMOGRAPHY; RADIOTHERAPY; SAFETY MARGINS

Citation Formats

Kriz, Jan, Reinartz, Gabriele, Dietlein, Markus, Kobe, Carsten, Kuhnert, Georg, Haverkamp, Heinz, Haverkamp, Uwe, Engenhart-Cabillic, Rita, Herfarth, Klaus, Lukas, Peter, Schmidberger, Heinz, Staar, Susanne, Hegerfeld, Kira, Baues, Christian, Engert, Andreas, and Eich, Hans Theodor, E-mail: hans.eich@ukmuenster.de. Relapse Analysis of Irradiated Patients Within the HD15 Trial of the German Hodgkin Study Group. United States: N. p., 2015. Web. doi:10.1016/J.IJROBP.2015.01.048.
Kriz, Jan, Reinartz, Gabriele, Dietlein, Markus, Kobe, Carsten, Kuhnert, Georg, Haverkamp, Heinz, Haverkamp, Uwe, Engenhart-Cabillic, Rita, Herfarth, Klaus, Lukas, Peter, Schmidberger, Heinz, Staar, Susanne, Hegerfeld, Kira, Baues, Christian, Engert, Andreas, & Eich, Hans Theodor, E-mail: hans.eich@ukmuenster.de. Relapse Analysis of Irradiated Patients Within the HD15 Trial of the German Hodgkin Study Group. United States. https://doi.org/10.1016/J.IJROBP.2015.01.048
Kriz, Jan, Reinartz, Gabriele, Dietlein, Markus, Kobe, Carsten, Kuhnert, Georg, Haverkamp, Heinz, Haverkamp, Uwe, Engenhart-Cabillic, Rita, Herfarth, Klaus, Lukas, Peter, Schmidberger, Heinz, Staar, Susanne, Hegerfeld, Kira, Baues, Christian, Engert, Andreas, and Eich, Hans Theodor, E-mail: hans.eich@ukmuenster.de. 2015. "Relapse Analysis of Irradiated Patients Within the HD15 Trial of the German Hodgkin Study Group". United States. https://doi.org/10.1016/J.IJROBP.2015.01.048.
@article{osti_22458692,
title = {Relapse Analysis of Irradiated Patients Within the HD15 Trial of the German Hodgkin Study Group},
author = {Kriz, Jan and Reinartz, Gabriele and Dietlein, Markus and Kobe, Carsten and Kuhnert, Georg and Haverkamp, Heinz and Haverkamp, Uwe and Engenhart-Cabillic, Rita and Herfarth, Klaus and Lukas, Peter and Schmidberger, Heinz and Staar, Susanne and Hegerfeld, Kira and Baues, Christian and Engert, Andreas and Eich, Hans Theodor, E-mail: hans.eich@ukmuenster.de},
abstractNote = {Purpose: To determine, in the setting of advanced-stage of Hodgkin lymphoma (HL), whether relapses occur in the irradiated planning target volume and whether the definition of local radiation therapy (RT) used by the German Hodgkin Study Group (GHSG) is adequate, because there is no harmonization of field and volume definitions among the large cooperative groups in the treatment of advanced-stage HL. Methods and Materials: All patients with residual disease of ≥2.5 cm after multiagent chemotherapy (CTX) were evaluated using additional positron emission tomography (PET), and those with a PET-positive result were irradiated with 30 Gy to the site of residual disease. We re-evaluated all sites of disease before and after CTX, as well as the PET-positive residual tumor that was treated in all relapsed patients. Documentation of radiation therapy (RT), treatment planning procedures, and portal images were carefully analyzed and compared with the centrally recommended RT prescription. The irradiated sites were compared with sites of relapse using follow-up computed tomography scans. Results: A total of 2126 patients were enrolled, and 225 patients (11%) received RT. Radiation therapy documents of 152 irradiated patients (68%) were analyzed, with 28 irradiated patients (11%) relapsing subsequently. Eleven patients (39%) had an in-field relapse, 7 patients (25%) relapsed outside the irradiated volume, and an additional 10 patients (36%) showed mixed in- and out-field relapses. Of 123 patients, 20 (16%) with adequately performed RT relapsed, compared with 7 of 29 patients (24%) with inadequate RT. Conclusions: The frequency and pattern of relapses suggest that local RT to PET-positive residual disease is sufficient for patients in advanced-stage HL. Insufficient safety margins of local RT may contribute to in-field relapses.},
doi = {10.1016/J.IJROBP.2015.01.048},
url = {https://www.osti.gov/biblio/22458692}, journal = {International Journal of Radiation Oncology, Biology and Physics},
issn = {0360-3016},
number = 1,
volume = 92,
place = {United States},
year = {Fri May 01 00:00:00 EDT 2015},
month = {Fri May 01 00:00:00 EDT 2015}
}